Table 1 Patients baseline characteristics and disease characteristics in the overall cohort and by subgroups.

From: SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia

Parameters N (%)

Patients with CLL (N = 23)

 

Overall cohort

Humoral response negative T cell response negative

Humoral response negative, T cell response positive

Humoral response positive, T cell response negative

Humoral response positive, T cell response positive

Overall COVID-19 vaccine immune response

 

8 (38.1)a

5 (23.8)a

5 (23.8)a

3 (14.3)a

Age, median (range) (years)

70 (46–79)

70.5 (48–79)

71.0 (53–79)

74.0 (62–77)

59.0 (49–62)

Age group (years)

 >65

13 (56.5)

6 (75.0)

3 (60.0)

4 (80.0)

0 (0.0)

 >70

11 (47.8)

4 (50.0)

3 (60.0)

4 (80.0)

0 (0.0)

Male sex

20 (87)

6 (75.0)

4 (80.0)

5 (100.0)

3 (100.0)

Disease / treatment status

 Treatment-naïve

1 (4.3)

0 (0.0)

0 (0.0)

1 (20.0)

0 (0.0)

 Previously treated

22 (95.7)

8 (100.0)

5 (100.0)

4 (80.0)

3 (100.0)

Treatment prior vaccination

22 (95.7)

    

Line of treatment, median (range)

2 (1–8)

2 (1–8)

3 (2–5)

2 (1–5)

2 (1–2)

1st line

6 (27.3)

2 (25.0)

0 (0.0)

2 (50.0)

1 (33.3)

>1st line

16 (72.7)

6 (75.0)

5 (100.0)

2 (40.0)

2 (66.7)

Treatment < 12 months prior vaccination

9 (40.9)

3 (37.5)

4 (80.0)

1 (25.0)

0 (0.0)

without anti CD20b

2 (9.1)

0 (0.0)

1 (20.0)

1 (20.0)

0 (0.0)

with anti CD20c

7 (31.8)

3 (37.5)

3 (60.0)

0 (0.0)

0 (0.0)

Type according to hierarchical modeld

21 (91.3)

    

del(17p)

4 (19.0)

3 (37.5)

1 (20.0)

0 (0.0)

0 (0.0)

del(11q)

5 (23.8)

1 (12.5)

1 (20.0)

1 (33.3)

2 (66.7)

Trisomy 12

4 (19.0)

1 (12.5)

0 (0.0)

0 (0.0)

1 (33.3)

No abnormalities

1 (4.8)

0 (0.0)

0 (0.0)

1 (33.3)

0 (0.0)

del(13q) [single]

7 (33.3)

3 (37.5)

3 (60.0)

1 (33.3)

0 (0.0)

IGHV mutational status

18 (78.3)

    

Unmutated

13 (72.2)

6 (75.0)

2 (66.7)

2 (66.7)

2 (100.0)

Mutated

5 (27.8)

2 (25.0)

1 (33.3)

1 (33.3)

0 (0.0)

TP53 mutational status

19 (82.6)

    

Mutated

2 (10.5)

5 (71.4)

4 (100.0)

3 (100.0)

3 (100.0)

Unmutated

17 (89.5)

2 (28.6)

0 (0.0)

0 (0.0)

0 (0.0)

  1. aHumoral and T cell response measured in 21/23 patients.
  2. bAcalabrutinib, Ibrutinib.
  3. cObinutuzumab, Obinutuzumab/Venetoclax, Acalabrutinib/Obinutuzumab, Acalabrutinib/Obinutuzumab/Venetoclax.
  4. dCytogenetic subgroups were determined according to the hierarchical model of Döhner et al. [11].
Back to article page